Advances in Biochemistry

| Peer-Reviewed |

The Effect of Serum Free Testosterone Level on Glycemic Control and Atherosclerosis in Type 2 Diabetic Men

Received: 10 May 2014    Accepted: 29 May 2014    Published: 10 June 2014
Views:       Downloads:

Share This Article

Abstract

Background: Atherosclerosis is a complex disease of the arteries characterized by endothelial dysfunction, vascular inflammation, and the build-up of lipids within the intima of the vessel wall. Testosterone has a central or permissive role in pathogenesis of the metabolic syndrome and type 2 diabetes. Insulin resistance is associated with several CVD risk factors such as obesity, dyslipidaemia, hypertension and the proinflammatory state. We aim to disclose the relationship between serum testosterone concentration and carotid atherosclerosis and its risk factors in men with type 2 diabetes. Patients and methods: The study population comprised 123 consecutive men of Type 2 diabetes. Retinopathy and nephropathy were ranked and graded respectively. Cardiovascular disease was defined as the presence of previous myocardial infarction or cerebral infarction. Total cholesterol and triglyceride concentrations were determined and hemoglobin Alc was measured. Assessment for the presence of carotid atherosclerosis was done, using ultrasonographic measurement of carotid intima media thickness (IMT). The relationship between serum testosterone concentration and carotid intima-media thickness IMT was investigated in all patients. Results: The mean of IMT for all patients was 0.96 ± 0.28 mm. Mean IMT was significantly greater in patients with lower concentrations of F-tes than in patients with higher concentrations of F-tes. (P= 0.038). Relationship between serum free testosterone concentration and other variables showed a negative correlation with patients’ age, patients’ age at onset, duration of diabetes, BMI, HbA1c, systolic and diastolic blood pressure, and total cholesterol concentrations and mean IMT in men with type 2 diabetes. No significant correlation was found between F-tes with triglyceride and negative correlation with mean IMT. Conclusion: Serum free testosterone concentration was found to be low in type 2 diabetic men. It has a negative correlation with patients’ age, patients’ age at onset of the disease, duration of diabetes, BMI and HbA1c, total cholesterol concentrations systolic and diastolic blood pressure and mean IMT. This may disclose the different mechanisms played by testosterone in the pathogenesis of cardiovascular risk in men with type 2 diabetes.

DOI 10.11648/j.ab.20140202.12
Published in Advances in Biochemistry (Volume 2, Issue 2, April 2014)
Page(s) 34-39
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Testosterone, Atherosclerosis, Type 2 Diabetes Mellitus

References
[1] Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. J Endocrinol. 2013a May; 7; 217(3):R47-71.
[2] Channer KS: Endogenous testosterone levels and cardiovascular disease in healthy men. Heart June 2011, 97 (11). 867- 869
[3] Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K,.: Testosterone and Sex Hormone- Binding Globulin Predict the Metabolic Syndrome and Diabetes in Middle-Aged Men. 10.2337/diacare.27.5.1036 Diabetes Diabetes Care. 2004 May;27(5):1036-41.
[4] Mayes JS, Watson GH: Direct effects of sex steroid hormones on adipose tissues and obesity, Obes Rev 2004, 5:197-216.
[5] Kohler TS, Kim J, Feia K, Bodie J, Johnson N, Makhlouf A, et al. Prevalence of androgen deficiency in men with erectile dysfunction. Urology 2008;71: 693-7.
[6] Rezvani MR, Saadatjou SA, Sorouri S, Hassanpour Fard M. Comparison of serum free testosterone, luteinizing hormone and follicle stimulating hormone levels in diabetics and non-diabetics men- a case-control study. J Res Health Sci 2012;12:98-100
[7] Tamler R, Deveney T. Hypogonadism, erectile dysfunction, and type 2 diabetes mellitus: What the clinician needs to know. Postgrad Med 2010;122:165-75
[8] Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, Macisaac RJ, Clarke S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 2008;93:1834-40
[9] Soriguer F, Rubio-Martin E, Fernandez D, Valdes S, Garcia-Escobar E, Mar-tin-Nunez GM, et al. Testosterone, SHBG and risk of type 2 diabetes in the second evaluation of the Pizarra cohort study. Eur J Clin Invest 2012;42:79-85
[10] Vangipurapu J, Stančáková A, Kuulasmaa T, Soininen P, Kangas AJ, Ala-Korpela M, Kuusisto J, Laakso M. Association between liver insulin resistance and cardiovascular risk factors. J Intern Med. 2012 Oct;272(4):402-8
[11] Yu Q, Gao F, Ma XL. Insulin says NO to cardiovascular disease. Cardiovasc Res. 2011 Feb; 15; 89(3):516-24.
[12] The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2002; 25:S5-S20
[13] Ishizaka N, Ishizaka Y, Takahashi E, Tooda E, Hashimoto H, Nagai R, Yamakado M: Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet. 2002; 359: 133–135.
[14] Helaly MA1, Daoud E, El-Mashad N. Does the Serum Testosterone Level Have a Relation to Coronary Artery Disease in Elderly Men? Curr Gerontol Geriatr Res. 2011; 2011: 791765.
[15] Michiaki Fukui. MDJ, Yoshihiro Kitagawa. MDi and Naoto Nakamura, MD2. Association Between Serum Testosterone Concentration and Carotid Atherosclerosis in Men With Type 2 DiabetesDiabetes Care June 2003; 26 (6) 1869-1873
[16] Fukui M, Kitagawa Y, Nakamura N, Kadono M, Mogami S, Hirata C,. Diabetes Care. Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes.2003 Jun; 26(6):1869-73.
[17] Svartberg J, von Mühlen D, Mathiesen E, Joakimsen O, Bonaa KH, Stensland-Bugge E. Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med. 2006 Jun; 259(6):576-82.
[18] Firtser S, Juonala M, Magnussen CG, Jula A, Loo BM, et al. Relation of total and free testosterone and sex hormone binding globulin with cardiovascular risk factors in men aged 24–45 years. The Cardiovascular Risk in Young Finns Study. Atherosclerosis 2012; 222: 257–62.
[19] Soisson V, Brailly TS, Empana JP, Feart C, Ryan J, et al. Low plasma testosterone and elevated carotid intima-media thickness: importance of low grade inflammation in elderly men. Atherosclerosis 2012; 223: 244–9.
[20] Nakamura Y, Suzuki T, Igarashi K, Kanno J, Furukawa T, Tazawa C, et al. PTOV1: a novel testosterone-induced atherogenic gene in human aorta. J Pathol. 2006; 209:522-531.
[21] Barud W, Palusiński R, Bełtowski J & Wojcicka G. Inverse relationship between total testosterone and anti-oxidized low density lipoprotein antibody levels in ageing males. Atherosclerosis 2002; 164(2):283-8.
[22] Akinloye O, Blessing Popoola B, Bolanle Ajadi M, Gregory Uche-chukwu J, Pius Oparinde D. Hypogonadism and Metabolic Syndrome in Nigerian Male Patients With Both Type 2 Diabetes and Hypertension. Int J Endocrinol Metab. 2014 Jan 1;12(1) :e10749
[23] Heufelder AE, Saad F, Bunck MC, Gooren L, Fifty‑two‑week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009; 30: 726.
[24] Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011; 34: 828–37.
[25] Brodsky IG, Balagopal P, Nair KS: Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men: a clinical research center study. J Clin Endocrinol Metab. 1996; 81:3469– 3475,
[26] Boyanov M, Boneva Z, Christov V. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6: 1–7.
[27] Kapoor D, Goodwin E, Channer K, Jones T. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899–906.
[28] Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011; 34:1669–1675.
[29] Agledahl I, Hansen JB & Svartberg J. Impact of testosterone treatment on postprandial triglyceride metabolism in elderly men with subnormal testosterone levels. Scand J Clin Lab Invest. 2008; 68(7):641-8.
[30] Saad F, Gooren LJ, Haider A & Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl. 2008; 29(1):102-5.
[31] Fukui M, Tanaka M, Hasegawa G, Yoshikawa T, Nakamura N. Association between Serum Bioavailable Testosterone Concentration and the Ratio of Glycated Albumin to Glycated Hemoglobin in Men with Type 2 Diabetes. Diabetes Care. 2008 Mar;31(3):397-401.
[32] Kelly DM, Jones TH. Testosterone: a metabolic hormone in health and disease. J Endocrinol 2013b; 217: R25–45.
[33] Sato K, Iemitsu M, Aizawa K, Ajisaka R. Testosterone and DHEA activate the glucose metabolism‑related signaling pathway in skeletal muscle. Am J Physiol Endocrinol Metab. 2008; 294: E961–8.
[34] Cai X, Tian Y, Wu T, Cao CX, Li H, Wang KJ. Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Asian Journal of Andrology 2014; 16(1): 146-152.
[35] Keating NL, O'Malley AJ, Smith MR. Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer. J Clin Oncol. 2006; 24(27):4448-56.
[36] Jones TH. Effects of testosterone on Type 2 diabetes and components of the metabolic syndrome. J Diabetes. 2010 ; 2(3):146-56.
[37] Losel RM, Falkenstein E, Feuring M, Schultz A, Tillmann HC, Rossol- Haseroth K, et al. steroid action: controversies, questions, and answers. Physiol Rev. 2003; 83:965–1016.
[38] Pi M, Parrill AL, Quarles LD. GPRC6A mediates the non-genomic effects of steroids. J Biol Chem. 2010; 285:39953–39964.
[39] Chignalia AZ, Schuldt EZ, Camargo LL, Montezano AC, Callera GE, Laurindo FR, et al. Testosterone induces vascular smooth muscle cell migration by NADPH oxidase and c-Src– dependent pathways. Hypertension. 2012;59:1263–1271.
Author Information
  • Department of Medical Biochemistry, Faculty of Medicine, Mansoura University, Mansoura, Egypt

  • Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt

  • Department of Internal medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt

  • Department of Physiology, Faculty of medicine, El Fayoum University, El Fayoum, Egypt

Cite This Article
  • APA Style

    Dalia A. Shaheen, Doaa A. Shahin, Alaa Aldeen Habib, Amani M. El Amin Ali. (2014). The Effect of Serum Free Testosterone Level on Glycemic Control and Atherosclerosis in Type 2 Diabetic Men. Advances in Biochemistry, 2(2), 34-39. https://doi.org/10.11648/j.ab.20140202.12

    Copy | Download

    ACS Style

    Dalia A. Shaheen; Doaa A. Shahin; Alaa Aldeen Habib; Amani M. El Amin Ali. The Effect of Serum Free Testosterone Level on Glycemic Control and Atherosclerosis in Type 2 Diabetic Men. Adv. Biochem. 2014, 2(2), 34-39. doi: 10.11648/j.ab.20140202.12

    Copy | Download

    AMA Style

    Dalia A. Shaheen, Doaa A. Shahin, Alaa Aldeen Habib, Amani M. El Amin Ali. The Effect of Serum Free Testosterone Level on Glycemic Control and Atherosclerosis in Type 2 Diabetic Men. Adv Biochem. 2014;2(2):34-39. doi: 10.11648/j.ab.20140202.12

    Copy | Download

  • @article{10.11648/j.ab.20140202.12,
      author = {Dalia A. Shaheen and Doaa A. Shahin and Alaa Aldeen Habib and Amani M. El Amin Ali},
      title = {The Effect of Serum Free Testosterone Level on Glycemic Control and Atherosclerosis in Type 2 Diabetic Men},
      journal = {Advances in Biochemistry},
      volume = {2},
      number = {2},
      pages = {34-39},
      doi = {10.11648/j.ab.20140202.12},
      url = {https://doi.org/10.11648/j.ab.20140202.12},
      eprint = {https://download.sciencepg.com/pdf/10.11648.j.ab.20140202.12},
      abstract = {Background: Atherosclerosis is a complex disease of the arteries characterized by endothelial dysfunction, vascular inflammation, and the build-up of lipids within the intima of the vessel wall. Testosterone has a central or permissive role in pathogenesis of the metabolic syndrome and type 2 diabetes. Insulin resistance is associated with several CVD risk factors such as obesity, dyslipidaemia, hypertension and the proinflammatory state. We aim to disclose the relationship between serum testosterone concentration and carotid atherosclerosis and its risk factors in men with type 2 diabetes. Patients and methods: The study population comprised 123 consecutive men of Type 2 diabetes. Retinopathy and nephropathy were ranked and graded respectively. Cardiovascular disease was defined as the presence of previous myocardial infarction or cerebral infarction. Total cholesterol and triglyceride concentrations were determined and hemoglobin Alc was measured. Assessment for the presence of carotid atherosclerosis was done, using ultrasonographic measurement of carotid intima media thickness (IMT). The relationship between serum testosterone concentration and carotid intima-media thickness IMT was investigated in all patients. Results: The mean of IMT for all patients was 0.96 ± 0.28 mm. Mean IMT was significantly greater in patients with lower concentrations of F-tes than in patients with higher concentrations of F-tes. (P= 0.038). Relationship between serum free testosterone concentration and other variables showed a negative correlation with patients’ age, patients’ age at onset, duration of diabetes, BMI, HbA1c, systolic and diastolic blood pressure, and total cholesterol concentrations and mean IMT in men with type 2 diabetes. No significant correlation was found between F-tes with triglyceride and negative correlation with mean IMT. Conclusion: Serum free testosterone concentration was found to be low in type 2 diabetic men. It has a negative correlation with patients’ age, patients’ age at onset of the disease, duration of diabetes, BMI and HbA1c, total cholesterol concentrations systolic and diastolic blood pressure and mean IMT. This may disclose the different mechanisms played by testosterone in the pathogenesis of cardiovascular risk in men with type 2 diabetes.},
     year = {2014}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - The Effect of Serum Free Testosterone Level on Glycemic Control and Atherosclerosis in Type 2 Diabetic Men
    AU  - Dalia A. Shaheen
    AU  - Doaa A. Shahin
    AU  - Alaa Aldeen Habib
    AU  - Amani M. El Amin Ali
    Y1  - 2014/06/10
    PY  - 2014
    N1  - https://doi.org/10.11648/j.ab.20140202.12
    DO  - 10.11648/j.ab.20140202.12
    T2  - Advances in Biochemistry
    JF  - Advances in Biochemistry
    JO  - Advances in Biochemistry
    SP  - 34
    EP  - 39
    PB  - Science Publishing Group
    SN  - 2329-0862
    UR  - https://doi.org/10.11648/j.ab.20140202.12
    AB  - Background: Atherosclerosis is a complex disease of the arteries characterized by endothelial dysfunction, vascular inflammation, and the build-up of lipids within the intima of the vessel wall. Testosterone has a central or permissive role in pathogenesis of the metabolic syndrome and type 2 diabetes. Insulin resistance is associated with several CVD risk factors such as obesity, dyslipidaemia, hypertension and the proinflammatory state. We aim to disclose the relationship between serum testosterone concentration and carotid atherosclerosis and its risk factors in men with type 2 diabetes. Patients and methods: The study population comprised 123 consecutive men of Type 2 diabetes. Retinopathy and nephropathy were ranked and graded respectively. Cardiovascular disease was defined as the presence of previous myocardial infarction or cerebral infarction. Total cholesterol and triglyceride concentrations were determined and hemoglobin Alc was measured. Assessment for the presence of carotid atherosclerosis was done, using ultrasonographic measurement of carotid intima media thickness (IMT). The relationship between serum testosterone concentration and carotid intima-media thickness IMT was investigated in all patients. Results: The mean of IMT for all patients was 0.96 ± 0.28 mm. Mean IMT was significantly greater in patients with lower concentrations of F-tes than in patients with higher concentrations of F-tes. (P= 0.038). Relationship between serum free testosterone concentration and other variables showed a negative correlation with patients’ age, patients’ age at onset, duration of diabetes, BMI, HbA1c, systolic and diastolic blood pressure, and total cholesterol concentrations and mean IMT in men with type 2 diabetes. No significant correlation was found between F-tes with triglyceride and negative correlation with mean IMT. Conclusion: Serum free testosterone concentration was found to be low in type 2 diabetic men. It has a negative correlation with patients’ age, patients’ age at onset of the disease, duration of diabetes, BMI and HbA1c, total cholesterol concentrations systolic and diastolic blood pressure and mean IMT. This may disclose the different mechanisms played by testosterone in the pathogenesis of cardiovascular risk in men with type 2 diabetes.
    VL  - 2
    IS  - 2
    ER  - 

    Copy | Download

  • Sections